false
English
Catalog
2021 World Conference on Lung Cancer (Posters)
FP12. The Intrinsic Limitation and Clinical Impact ...
FP12. The Intrinsic Limitation and Clinical Impact of Mutant Allele-Specific Real-Time PCR-Based EGFR Mutation Assay in NSCLC
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Jiayi Shen from Taipei Veterans General Hospital discusses the limitations of the COBAS EGFR mutation test, a commonly used assay in non-small-cell lung cancer. The test has an intrinsic detection limitation due to its primer designs, resulting in a false negative rate of 8.1%. In a retrospective cohort study, using next-generation sequencing (NGS), it was found that the false negative rate of the COBAS test increased to 11.3%. The study also identified other druggable driver mutations, such as ROS1, BRAF, and met exome 14 skipping, in 64.5% of patients. The findings highlight the importance of comprehensive molecular analysis in determining treatment strategies and improving clinical outcomes.
Asset Subtitle
Chia-I Shen
Meta Tag
Speaker
Chia-I Shen
Topic
Predictive Tumor Based Assays/ Biomarkers/ Pathology
Keywords
COBAS EGFR mutation test
limitations
false negative rate
next-generation sequencing
druggable driver mutations
×
Please select your language
1
English
5
普通话
11
Dutch